Literature DB >> 26475526

Aspirin-Exacerbated Diseases: Advances in Asthma with Nasal Polyposis, Urticaria, Angioedema, and Anaphylaxis.

Whitney Stevens1, Kathleen Buchheit2, Katherine N Cahill3.   

Abstract

Aspirin-exacerbated diseases are important examples of drug hypersensitivities and include aspirin-exacerbated respiratory disease (AERD), aspirin- or non-steroidal anti-inflammatory drug (NSAID)-induced urticaria/angioedema, and aspirin- or NSAID-induced anaphylaxis. While each disease subtype may be distinguished by unique clinical features, the underlying mechanisms that contribute to these phenotypes are not fully understood. However, the inhibition of the cyclooxygenase-1 enzyme is thought to play a significant role. Additionally, eosinophils, mast cells, and their products, prostaglandins and leukotrienes, have been identified in the pathogenesis of AERD. Current diagnostic and treatment strategies for aspirin-exacerbated diseases remain limited, and continued research focusing on each of the unique hypersensitivity reactions to aspirin is essential. This will not only advance the understanding of these disease processes, but also lead to the subsequent development of novel therapeutics that patients who suffer from aspirin-induced reactions desperately need.

Entities:  

Keywords:  Anaphylaxis; Angioedema; Aspirin hypersensitivity; Aspirin-exacerbated respiratory disease (AERD); Nasal polyposis; Urticaria

Mesh:

Substances:

Year:  2015        PMID: 26475526     DOI: 10.1007/s11882-015-0569-2

Source DB:  PubMed          Journal:  Curr Allergy Asthma Rep        ISSN: 1529-7322            Impact factor:   4.806


  97 in total

1.  Participation of prostaglandins in pathogenesis of aspirin-sensitive asthma.

Authors:  A Szczeklik; R J Gryglewski; G Czerniawska-Mysik
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1977       Impact factor: 3.000

2.  Aspirin as a therapeutic agent in cardiovascular disease: a statement for healthcare professionals from the American Heart Association.

Authors:  C H Hennekens; M L Dyken; V Fuster
Journal:  Circulation       Date:  1997-10-21       Impact factor: 29.690

3.  Aspirin-exacerbated cutaneous disease (AECD) is a distinct subphenotype of chronic spontaneous urticaria.

Authors:  M Sánchez-Borges; F Caballero-Fonseca; A Capriles-Hulett; L González-Aveledo
Journal:  J Eur Acad Dermatol Venereol       Date:  2014-09-29       Impact factor: 6.166

4.  Prominent role of IFN-γ in patients with aspirin-exacerbated respiratory disease.

Authors:  John W Steinke; Lixia Liu; Phillip Huyett; Julie Negri; Spencer C Payne; Larry Borish
Journal:  J Allergy Clin Immunol       Date:  2013-06-24       Impact factor: 10.793

5.  Association analysis of FABP1 gene polymorphisms with aspirin-exacerbated respiratory disease in asthma.

Authors:  Hun Soo Chang; Jong Sook Park; Hye-Rim Shin; Byung Lae Park; Hyoung Doo Shin; Choon-Sik Park
Journal:  Exp Lung Res       Date:  2014-10-22       Impact factor: 2.459

6.  Low doses of acetylsalicylic acid increase risk of gastrointestinal bleeding in a meta-analysis.

Authors:  Angel Lanas; Ping Wu; Jennie Medin; Edward J Mills
Journal:  Clin Gastroenterol Hepatol       Date:  2011-06-06       Impact factor: 11.382

7.  Platelet activation markers overexpressed specifically in patients with aspirin-exacerbated respiratory disease.

Authors:  Chihiro Mitsui; Keiichi Kajiwara; Hiroaki Hayashi; Jun Ito; Haruhisa Mita; Emiko Ono; Noritaka Higashi; Yuma Fukutomi; Kiyoshi Sekiya; Takahiro Tsuburai; Kazuo Akiyama; Kazuhiko Yamamoto; Masami Taniguchi
Journal:  J Allergy Clin Immunol       Date:  2015-07-17       Impact factor: 10.793

8.  An economic analysis of aspirin desensitization in aspirin-exacerbated respiratory disease.

Authors:  Marcus Shaker; Ano Lobb; Pamela Jenkins; Daniel O'Rourke; Steve K Takemoto; Salil Sheth; Thomas Burroughs; Mark S Dykewicz
Journal:  J Allergy Clin Immunol       Date:  2007-08-22       Impact factor: 10.793

9.  Cysteinyl leukotrienes overproduction and mast cell activation in aspirin-provoked bronchospasm in asthma.

Authors:  K Sladek; A Szczeklik
Journal:  Eur Respir J       Date:  1993-03       Impact factor: 16.671

10.  The SNP rs3128965 of HLA-DPB1 as a genetic marker of the AERD phenotype.

Authors:  Seung-Hyun Kim; Bo-Young Cho; Hyunna Choi; Eun-Soon Shin; Young-Min Ye; Jong-Eun Lee; Hae-Sim Park
Journal:  PLoS One       Date:  2014-12-23       Impact factor: 3.240

View more
  6 in total

Review 1.  [Personalized medicine in allergology].

Authors:  W Pfützner; J Pickert; C Möbs
Journal:  Hautarzt       Date:  2019-01       Impact factor: 0.751

2.  Expression of DACT1 in children with asthma and its regulation mechanism.

Authors:  Cunxue Zhang; Peili Yang; Yan Chen; Jing Liu; Xiutai Yuan
Journal:  Exp Ther Med       Date:  2018-01-05       Impact factor: 2.447

Review 3.  Practical Management of Patients with a History of Immediate Hypersensitivity to Common non-Beta-Lactam Drugs.

Authors:  Eric Macy
Journal:  Curr Allergy Asthma Rep       Date:  2016-01       Impact factor: 4.806

Review 4.  Pediatric Angioedema.

Authors:  Debendra Pattanaik; Jay Adam Lieberman
Journal:  Curr Allergy Asthma Rep       Date:  2017-08-08       Impact factor: 4.806

Review 5.  Aspirin Intolerance: Experimental Models for Bed-to-Bench.

Authors:  Masamichi Yamashita
Journal:  Curr Drug Targets       Date:  2016       Impact factor: 3.465

Review 6.  Orofacial manifestations of adverse drug reactions: a review study.

Authors:  Sedigheh Bakhtiari; Marziye Sehatpour; Hamed Mortazavi; Mahin Bakhshi
Journal:  Clujul Med       Date:  2018-01-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.